Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity - PubMed
4 hours ago
- #Inflammation
- #Atherosclerosis
- #GLP-1 receptor agonists
- GLP-1 receptor agonists (GLP-1 RAs) reduce atherosclerosis progression and inflammation in normoglycemic, non-obese rabbits, as shown by decreased plaque volume and cathepsin activity.
- Clinical data from 47,324 participants indicate GLP-1 RA use is associated with lower inflammatory biomarkers and reduced major adverse cardiovascular events (MACE), regardless of hyperglycemia or obesity status.
- In vitro studies confirm GLP-1 RAs suppress cathepsin activity and inflammatory mediators in macrophages, supporting their anti-inflammatory and anti-atherosclerotic effects.
- Mediation analysis suggests that inflammatory biomarkers partially mediate the cardiovascular benefits of GLP-1 RAs in clinical settings.